News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
264,495 Results
Type
Article (14109)
Company Profile (282)
Press Release (250104)
Section
Business (79452)
Career Advice (153)
Deals (13218)
Drug Delivery (35)
Drug Development (50399)
Employer Resources (31)
FDA (5704)
Job Trends (5126)
News (144292)
Policy (10025)
Tag
Academia (907)
Alliances (21604)
Alzheimer's disease (796)
Antibody-drug conjugate (ADC) (75)
Approvals (5706)
Artificial intelligence (93)
Bankruptcy (102)
Best Places to Work (4562)
Biotechnology (232)
Breast cancer (130)
Cancer (1112)
Cardiovascular disease (88)
Career advice (133)
CAR-T (92)
Cell therapy (272)
Clinical research (40560)
Collaboration (436)
Compensation (184)
COVID-19 (1024)
C-suite (117)
Cystic fibrosis (74)
Data (1150)
Diabetes (105)
Diagnostics (1278)
Earnings (29209)
Events (47656)
Executive appointments (353)
FDA (6210)
Funding (414)
Gene editing (76)
Gene therapy (199)
GLP-1 (343)
Government (1072)
Healthcare (6570)
Infectious disease (1075)
Inflammatory bowel disease (105)
IPO (7247)
Job creations (859)
Job search strategy (128)
Layoffs (196)
Legal (1383)
Lung cancer (164)
Manufacturing (103)
Medical device (2576)
Medtech (2577)
Mergers & acquisitions (6205)
Metabolic disorders (315)
Neuroscience (1109)
NextGen: Class of 2025 (2012)
Non-profit (853)
Northern California (1339)
Obesity (166)
Opinion (96)
Parkinson's disease (89)
Patents (86)
People (25352)
Phase I (14314)
Phase II (18873)
Phase III (11924)
Pipeline (504)
Postmarket research (852)
Preclinical (5996)
Radiopharmaceuticals (209)
Rare diseases (248)
Real estate (1414)
Regulatory (8439)
Research institute (932)
Series A (82)
Southern California (1188)
Startups (1968)
United States (10533)
Vaccines (189)
Weight loss (96)
Date
Last 7 days (339)
Last 30 days (1449)
Last 365 days (20375)
2025 (2646)
2024 (20553)
2023 (22415)
2022 (26823)
2021 (27805)
2020 (23361)
2019 (16229)
2018 (11740)
2017 (13745)
2016 (11841)
2015 (14351)
2014 (10392)
2013 (7485)
2012 (7534)
2011 (7615)
2010 (7428)
Location
Africa (149)
Asia (17097)
Australia (2894)
California (3047)
Canada (965)
China (269)
Colorado (115)
Connecticut (130)
Delaware (72)
Europe (36779)
Florida (348)
Georgia (91)
Illinois (192)
Indiana (73)
Maryland (396)
Massachusetts (2386)
Minnesota (119)
New Jersey (762)
New York (835)
North Carolina (475)
Northern California (1339)
Ohio (98)
Pennsylvania (577)
South America (208)
Southern California (1188)
Texas (337)
Washington State (291)
264,495 Results for "rewind therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
CervoMed Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy Bodies
CervoMed Inc., a clinical stage company focused on developing treatments for age-related neurologic disorders, announced that it has completed enrollment in RewinD-LB, a Phase 2b trial evaluating neflamapimod in patients with dementia with Lewy bodies.
June 11, 2024
·
5 min read
Press Releases
CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies
December 10, 2024
·
8 min read
Press Releases
CervoMed Announces Last Patient Last Visit in Phase 2b RewinD-LB Trial of Neflamapimod for the Treatment of Early-Stage Dementia with Lewy Bodies (DLB)
October 15, 2024
·
6 min read
Drug Development
EIP Pharma Announces First Patient Dosed in RewinD-LB Phase 2b Clinical Trial Evaluating Neflamapimod in Dementia with Lewy Bodies
EIP Pharma Inc. today announced that the first patient has been dosed in the Company’s RewinD-LB Phase 2b clinical trial of neflamapimod for the treatment of patients with dementia with Lewy bodies (DLB).
August 14, 2023
·
12 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Press Releases
Tango Therapeutics to Present at Three Upcoming Investment Bank Conferences
February 20, 2025
·
1 min read
Press Releases
MiNK Therapeutics Regains Full Compliance with Nasdaq Listing Requirements
February 20, 2025
·
1 min read
Press Releases
Allogene Therapeutics Announces Participation in February Investor Conferences
February 4, 2025
·
2 min read
Press Releases
Denali Therapeutics Announces Upcoming Presentations on Hunter Syndrome (MPS II) and TransportVehicle™ Enabled Investigational Therapeutic Tividenofusp Alfa at the 2025 WORLDSymposium™
January 30, 2025
·
4 min read
Press Releases
MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs
February 12, 2025
·
6 min read
1 of 26,450
Next
